Wells Fargo’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.88K | Sell |
6,500
-40,040
| -86% | -$26.2K | ﹤0.01% | 6265 |
|
|
2026
Q1 | $36.3K | Sell |
46,540
-70,177
| -60% | -$59.2K | ﹤0.01% | 5559 |
|
|
2025
Q4 | $91.4K | Buy |
116,717
+5,658
| +5% | +$4.64K | ﹤0.01% | 5418 |
|
|
2025
Q3 | $80.1K | Sell |
111,059
-166,329
| -60% | -$754K | ﹤0.01% | 5416 |
|
|
2025
Q2 | $1.41M | Buy |
277,388
+109,169
| +65% | +$430K | ﹤0.01% | 3483 |
|
|
2025
Q1 | $508K | Buy |
168,219
+62,450
| +59% | +$228K | ﹤0.01% | 4090 |
|
|
2024
Q4 | $383K | Buy |
105,769
+103,269
| +4,131% | +$313K | ﹤0.01% | 4362 |
|
|
2024
Q3 | $4.4K | Buy |
2,500
+1,000
| +67% | +$1.82K | ﹤0.01% | 5941 |
|
|
2024
Q2 | $2.34K | Sell |
1,500
-412
| -22% | -$717 | ﹤0.01% | 5989 |
|
|
2024
Q1 | $3.73K | Buy |
1,912
+7
| +0.4% | +$12 | ﹤0.01% | 5937 |
|
|
2023
Q4 | $2.69K | Buy |
1,905
+30
| +2% | +$38 | ﹤0.01% | 6049 |
|
|
2023
Q3 | $2.96K | Sell |
1,875
-16
| -0.8% | -$30 | ﹤0.01% | 6041 |
|
|
2023
Q2 | $4.08K | Buy |
1,891
+37
| +2% | +$81 | ﹤0.01% | 6106 |
|
|
2023
Q1 | $3.89K | Buy |
1,854
+159
| +9% | +$348 | ﹤0.01% | 6104 |
|
|
2022
Q4 | $3.71K | Buy |
1,695
+9
| +0.5% | +$21 | ﹤0.01% | 5854 |
|
|
2022
Q3 | $6K | Buy |
1,686
+11
| +0.7% | +$37 | ﹤0.01% | 5870 |
|
|
2022
Q2 | $4K | Buy |
1,675
+16
| +1% | +$58 | ﹤0.01% | 6123 |
|
|
2022
Q1 | $9K | Hold |
1,659
| – | – | ﹤0.01% | 6325 |
|
|
2021
Q4 | $12K | Buy |
1,659
+71
| +4% | +$593 | ﹤0.01% | 6490 |
|
|
2021
Q3 | $15K | Buy |
1,588
+1,491
| +1,537% | +$8.92K | ﹤0.01% | 6079 |
|
|
2021
Q2 | $0 | Buy |
97
+35
| +56% | +$149 | ﹤0.01% | 7559 |
|
|
2021
Q1 | $0 | Hold |
62
| – | – | ﹤0.01% | 7483 |
|
|
2020
Q4 | $0 | Buy |
62
+7
| +13% | +$26 | ﹤0.01% | 7119 |
|
|
2020
Q3 | $0 | Buy |
55
+2
| +4% | +$8 | ﹤0.01% | 7016 |
|
|
2020
Q2 | $0 | Buy |
53
+7
| +15% | +$25 | ﹤0.01% | 6930 |
|
|
2020
Q1 | $0 | Buy |
+46
| New | +$199 | ﹤0.01% | 6915 |
|
|
2018
Q2 | – | Sell |
-1,411
| Closed | -$52K | – | 6624 |
|
|
2018
Q1 | $52K | Buy |
1,411
+88
| +7% | +$4.12K | ﹤0.01% | 5555 |
|
|
2017
Q4 | $65K | Buy |
+1,323
| New | +$81.3K | ﹤0.01% | 5465 |
|
|
2016
Q2 | – | Sell |
-33
| Closed | -$2K | – | 6369 |
|
|
2016
Q1 | $2K | Buy |
33
+32
| +3,200% | +$2.43K | ﹤0.01% | 6049 |
|
|
2015
Q4 | $0 | Sell |
1
-1
| -50% | -$142 | ﹤0.01% | 6455 |
|
|
2015
Q3 | $0 | Sell |
2
-20
| -91% | -$4.56K | ﹤0.01% | 6496 |
|
|
2015
Q2 | $6K | Buy |
+22
| New | +$6.83K | ﹤0.01% | 5971 |
|
Other funds holding ATYR
GCP
KCM
Wells Fargo's ATYR Position: Q2 2026 in Review
Wells Fargo reduced its aTyr Pharma (ATYR) stake by 86% in Q2 2026, selling an estimated $26.2K and leaving 6,500 shares worth $3.88K. The position accounts for ﹤0.01% of the portfolio, ranked #6265.
Wells Fargo first reported a position in ATYR in Q2 2015 and has held it in 32 quarters since. The position peaked at $1.41M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.
- Wells Fargo held 6,500 shares of aTyr Pharma worth $3.88K as of Q2 2026.
- Wells Fargo sold 40,040 aTyr Pharma shares in Q2 2026, an estimated $26.2K.
- aTyr Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6265 holding.
- Wells Fargo first reported a position in aTyr Pharma in Q2 2015 and has held it in 32 quarters since.
- Wells Fargo's aTyr Pharma position peaked at $1.41M in Q2 2025.
- 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.